Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
Rhea-AI Summary
Bionano (Nasdaq: BNGO) reported a peer-reviewed T-cell acute lymphoblastic leukemia (T-ALL) study in Modern Pathology using optical genome mapping (OGM).
In 91 T-ALL cases, OGM detected abnormalities in 97.8% of samples versus 55% for karyotyping, delivered added genomic insights in ~70%, identified 45 gene fusions (24 known, 21 novel), and supported refined T-ALL subtype classification in a single workflow.
AI-generated analysis. Not financial advice.
Positive
- Largest OGM T-ALL study with 91 cases analyzed across three platforms
- OGM detected abnormalities in 97.8% of T-ALL cases vs 55% by karyotyping
- OGM provided additional genomic insights in approximately 70% of T-ALL cases
- Identified 24 known and 21 novel T-ALL gene fusions
- Copy number changes detected in 93% of cases using OGM
- Study supports OGM plus NGS as complementary for T-ALL genomics
Negative
- None.
News Market Reaction – BNGO
On the day this news was published, BNGO declined 1.61%, reflecting a mild negative market reaction. This price movement removed approximately $229K from the company's valuation, bringing the market cap to $14.00M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with FEMY up 9.59% and MLSS down 3.52%, suggesting today’s action was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 13 | Q1 2026 earnings | Negative | -4.8% | Q1 revenue growth with higher margins but a wider loss and cautious outlook. |
| May 06 | Leadership change | Negative | +4.7% | CEO removal and appointment of interim CEO and new lead independent director. |
| May 05 | OGM rare disease data | Positive | +0.0% | Report of 28 OGM publications in rare disease, up ~56% year over year. |
| Apr 29 | Earnings call announcement | Neutral | +0.0% | Scheduling of Q1 2026 earnings release and webcast details. |
| Apr 02 | OGM myeloma study | Positive | +0.8% | Multicenter study showing OGM outperforming traditional methods in multiple myeloma. |
OGM-related publications have generally seen small or positive reactions, while earnings and leadership changes have produced sharper, but mixed, moves.
Over the last two months, Bionano reported Q1 2026 results with $6.7M revenue and a negative price reaction, while a leadership transition on May 6 drew a positive move. Multiple news items highlighted growing validation of OGM, including a Modern Pathology multiple myeloma study analyzing 211 samples and a rare-disease update citing 28 publications and a ~56% increase year over year. Today’s T-ALL study adds another peer-reviewed data point reinforcing OGM’s performance in hematologic cancers.
Regulatory & Risk Context
An effective S-3 shelf filed on May 8, 2026 allows the company to offer up to $400,000,000 of securities for general corporate purposes, with no usage yet recorded and specific terms to be set by future prospectus supplements.
Market Pulse Summary
This announcement highlights peer-reviewed evidence that OGM detected abnormalities in 97.8% of T-ALL cases versus 55% for karyotyping, reinforcing Bionano’s positioning in complex blood cancers. It follows prior publications in multiple myeloma and rare diseases, building a consistent technical story. At a share price of $1.24, far below the $5.50 52-week high, investors may watch how such clinical validation translates into revenue growth and how the unused $400M shelf is ultimately deployed.
Key Terms
optical genome mapping medical
t-cell acute lymphoblastic leukemia medical
karyotyping medical
next-generation sequencing medical
copy number medical
gene fusions medical
structural variant analysis medical
cytogenetic medical
AI-generated analysis. Not financial advice.
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in
T-ALL is an aggressive form of pediatric and adult leukemia driven by a wide variety of complex genetic changes, many of which are too subtle or structurally complex to be detected by traditional methods. The disease is notoriously difficult to characterize fully, limiting the ability of researchers to study its biology, classify subtypes, and develop targeted therapies.
The 91-subject study compared OGM head-to-head against conventional karyotyping and next-generation sequencing (NGS) — the standard tools for evaluating T-ALL. Where karyotyping identified abnormalities in just
Key Highlights:
- 91 cases: of T-ALL cases analyzed across three platforms — OGM, conventional karyotyping, and NGS — making this study the largest OGM study of T-ALL conducted to date.
- High success rate for finding abnormalities: OGM identified chromosomal abnormalities in
97.8% of cases, compared to55% by conventional karyotyping — a dramatic improvement in detection for a disease where missed findings can leave the biology incompletely understood. - Broader picture in
70% of cases: OGM delivered clinically relevant genomic information beyond karyotyping in approximately70% of cases, uncovering abnormalities that standard methods missed — all without requiring additional testing. - 24 known + 21 novel gene fusions identified: OGM detected gene rearrangements in
80% of cases, including 24 known recurrent fusions and 21 newly identified fusions, pointing to potential new targets for T-ALL research. - Comprehensive sequence variant and copy number profiling: OGM identified copy number changes in
93% of cases. NGS detected sequence variants in92% of cases. The gene most frequently found to harbor variants was NOTCH1 (57% of cases). - Disease subtypes decoded: OGM uncovered distinct genomic patterns across T-ALL subtypes, supporting more precise biological classification of this heterogeneous disease.
- OGM can streamline workflows for T-ALL. T-ALL presents particular challenges for standard genomic analysis: samples often yield poor-quality material for karyotyping, and many of the most biologically important genetic changes are subtle, small-scale, or driven by rearrangements in non-coding regions of the genome. Conventional approaches typically require multiple sequential analyses to piece together a complete picture — a process that is time-consuming, costly, and incomplete. OGM can address these limitations with a genome-wide approach that captures the full landscape of genetic variation in a single workflow.
“This publication further strengthens the growing body of evidence supporting OGM as a powerful tool for resolving the genomic complexity of challenging childhood and adult blood cancers like T-ALL,
The full publication, Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia Using Optical Genome Mapping, Karyotyping, and Next-Generation Sequencing, is available in Modern Pathology at: https://www.modernpathology.org/article/S0893-3952(26)00029-3/
About Bionano Genomics
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “support,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; the ability and utility of OGM to substantially improve detection of relevant cytogenomic abnormalities in T-ALL compared with conventional karyotyping; the ability and utility of OGM to transform how this aggressive blood cancer is studied and understood; the ability and utility of OGM to provide critical genomic information that complements NGS; the ability and utility of OGM to streamline workflows and address limitations of standard genomic analysis with a genome-wide approach that captures the full landscape of genetic variation in a single workflow; the ability of OGM to outperform legacy cytogenomic methods; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; our ability to drive adoption of OGM and our technology solutions; and any other statements that are not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to substantially improve detection of relevant cytogenomic abnormalities in T-ALL compared with conventional karyotyping; the failure of OGM to transform how this aggressive blood cancer is studied and understood; the failure of OGM to provide critical genomic information that complements NGS; the failure of OGM to streamline workflows and address limitations of standard genomic analysis with a genome-wide approach that captures the full landscape of genetic variation in a single workflow; the failure of OGM to outperform legacy cytogenomic methods; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing international conflicts and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817
IR@bionano.com
